GENETIC TEST:
Dihydropyrimidine dehydrogenase deficiency/5-fluorouracil toxicity - Pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3)

FULL NAME:	Dihydropyrimidine dehydrogenase deficiency/5-fluorouracil toxicity - Pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3)
DESCRIPTION:	Using Sanger sequencing and/or SALSA MLPA, the presence of the following four variants in the DPYD gene is investigated: - c.1236G>A (rs56038477) or c.1129-5923C>G (rs75017182) - c.1905+1G>A (rs3918290) - c.1679T>G (rs55886062) - c.2846A>T (rs67376798) The c.1236 G>A variant is in linkage disequilibrium with the c.1129-5923C>G variant.
TEST TYPE:	Clinical
TEST SPECIALTY:	Molecular Genetics
TEST PURPOSE:	Therapeutic Management
SPECIMEN:	Peripheral (whole) blood on EDTA
METHOD CATEGORY:	Targeted variant analysis
METHOD TECHNIQUE:	Bi-directional Sanger Sequence analysis MLPA based techniques
RIZIV CODE:	565390-565401

ACCREDITATION (ISO 15189):	2021-07-08 / 2026-02-02
EQA:	• Dihydropyrimidine dehydrogenase deficiency, • Dihydropyrimidine dehydrogenase deficiency
TURNAROUND TIME (MAXIMUM):	7 calendar days
CREATED:	23 Dec 2019 - 12:24
CHANGED:	01 Mar 2023 - 14:47
URL:	https://laboboeken.nexuzhealth.com/pboek/internet/GHB%20CME/12619

RELATED CONTENT

Related Diseases

- Dihydropyrimidine dehydrogenase deficiency

Related Laboratories

- Centrum Menselijke Erfelijkheid - KUL

Related Analytes

- dihydropyrimidine dehydrogenase